Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Samsung Biologics faces suit from Amgen over bone biosimilars

15 August 2024 Amgen alleges infringement by proposed biosimilar versions of Prolia and XGEVA | Complaint accuses Samsung of failing to fully disclose biosimilar application and seeks injunction on bone-treatment products.

Biotechnology

Amgen and Sandoz settle dispute over blockbuster bone condition drugs

30 April 2024 Agreement clears the way for Sandoz to launch denosumab biosimilars in May 2025 | Dispute over multiple patents covering Prolia and Xgeva resolved.

Americas

Amgen sues generic drug maker over bone treatments

4 May 2023 Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.

More features

Why AI is changing the patent rules faster than anyone can keep up

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

The hidden code in life sciences deals

LSPN panel unpacks critical IP risks in deal-making

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

More on this story

Editor's picks

Editor's picks

More features